|ARHAI-Net||Antimicrobial Resistance and Healthcare-Associated Infections Network||ECDC||
Focus on surveillance, scientific advice, training and communication to address the threat of antimicrobial resistance and healthcare-associated infections.|
ARHAI integrated the former European programmes ESAC on antimicrobial consumption, EARSS on antimicrobial resistance, HELICS on healthcare-associated infections (surgical site infections; HAI in intensive care), and IPSE on a wider patient safety context.
|EIP||Emerging Infections Program||US-CDC||Prevention and control of infectious diseases by providing scientific information to monitor emergency problems, evaluate public health interventions, and inform policy.||https://www.cdc.gov/ncezid/dpei/eip/index.html|
|IMI||Innovative Medicines Initiative||EC & EFPIA||
Working group on accelerating development and access to innovative medicines, particularly in areas where there is an unmet need.|
IMI is the world’s biggest public-private partnership in life sciences.
|GIPCN||Global Infection Prevention and Control Network||WHO||GIPCN aims to enhance local, national and international coordination and collaboration in the field of IPC and to support WHO’s and countries’ efforts on IPC, from preparedness, to IPC systems and programmes’ strengthening, outbreak prevention and control, as well as capacity building for surveillance.||http://www.who.int/infection-prevention/about/GIPC_Network/en/|
|GLASS||Global Antimicrobial Resistance Surveillance System||WHO||GLASS promotes and supports a standardized approach to the collection, analysis and sharing of AMR data at a global level by encouraging and facilitating the establishment of national AMR surveillance systems that are capable of monitoring AMR trends and producing reliable and comparable data.||https://www.who.int/glass/partnerships/en/|
|JPIAMR||Joint Programming Initiative on Antimicrobial Resistance||EU||Basic and exploratory research on new antibiotics, stewardship of existing antibiotics, and control of the spread of antibiotic resistance between humans, animals, and the environment in a One Health perspective (26 countries globally).||https://www.jpiamr.eu/|
|POPS||Private Organizations for Patient Safety||WHO||Public-private partnership to harness industry strengths to align and improve implementation of WHO recommendations in different parts of the world.||http://www.who.int/infection-prevention/about/pops/en/|
|TATFAR||Trans-Atlantic Force for Antimicrobial Resistance||US-CDC||
Transatlantic collaboration between US-CDC, ECDC, EC, EFSA, FDA, AMA, OGHA, and USDHS.|
Improving appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities; preventing healthcare- and community-associated drug-resistant infections, and developing strategies for improving the pipeline of new antimicrobial drugs.
|Antibiotic Resistance Solutions Initiative||US-CDC||The initiative invests in national infrastructure to detect, respond, contain, and prevent resistant infections across healthcare settings, food, and communities. CDC funding supports all 50 state health departments, six local health departments, and Puerto Rico.||https://www.cdc.gov/drugresistance/solutions-initiative/index.html|
|Prevention EpiCenters||US-CDC||Collaborative research programme between the CDC’s division of healthcare quality promotion and academic investigators for conducting innovative infection prevention and control research.||https://www.cdc.gov/hai/epicenters/index.html|
|WHO SAVE LIVES: Clean Your Hands||WHO||WHO’s global annual campaign making a call to action for health workers every 5 May concerning preventing HAI through hand hygiene and IPC improvements .||http://www.who.int/infection-prevention/campaigns/clean-hands/en/|